Praxis Precision Medicines, Inc. is developing therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, a treatment for major depressive disorders and perimenopausal depression, and PRAX-944, for the treatment of essential tremor. Praxis Precision Medicines was incorporated in 2015 and is headquartered in Boston, MA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$3.07 | A | |
$8.24 | A | |
$24.29 | A |